Protecting intellectual properties, like the fractional radiofrequency, Morpheus8 technology, is a fundamental component of the InMode management team’s strategic plan to grow shareholder value.

Today, InMode announced that the U.S. Patent and Trademark Office has granted the company Patent No. 10.799.285 covering its Morpheus8 full body fractional radiofrequency (RF) technology.

Since its inception, InMode has invested significantly in research and development to independently design state-of-the-art electro-surgical bi-polar radiofrequency devices, bringing to market breakthrough surgical procedures for the face, body, skin, and women’s health and wellness.  Through its ongoing commitment to research and development, InMode is accredited with pioneering full body fractional RF technology through the commercialization of the Morpheus8 Subdermal Adipose Remodeling (SARD) device.

Protecting intellectual properties (IP) is a fundamental component of the InMode management team’s strategic plan to grow shareholder value. As a result, the company will categorically enforce its unique fractional IP to the full extent of the law.  Cease and desist notices have been recently issued to multiple North American companies manufacturing and marketing products or platforms infringing on InMode’s Patent No. 10.799.285.

Michael Kreindel, MD, InMode chief technology officer, said: “The reciprocating mechanism in RF fractional devices is a key feature for delivering fast and uniform treatments.  InMode is proud to be the first company to bring this technology to the medical aesthetics market.”

Source: plasticsurgerypractice.com

Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]